Enhanced Gene Therapy for Mucopolysaccharidosis Type I Treatment

This inventive concept improves upon existing gene therapy methods for treating mucopolysaccharidosis type I (MPS I) by providing more efficient, safer, and longer-lasting treatments through controlled release formulations, site-specific integration, and prenatal administration.

The original patent disclosed methods for treating MPS I using AAV vectors, but had limitations in terms of treatment efficacy, duration, and potential side effects. The new inventive concept addresses these limitations by introducing novel approaches to gene therapy, enabling more precise and sustained expression of the corrective iduronidase enzyme.

The new claims describe a system for treating MPS I comprising a gene therapy vector for expressing a corrective copy of the iduronidase enzyme in a controlled release formulation. This allows for stable levels of the enzyme in the circulation over an extended period, reducing the need for repeated administrations. Additionally, site-specific integration of the corrective transgene into the albumin locus of hepatocytes in vivo using engineered zinc finger nucleases enables precise and sustained expression of the enzyme. Prenatal administration of the corrective transgene in utero further expands the treatment options for MPS I. A biosensor-based system for monitoring treatment efficacy and adjusting the dose and duration of gene therapy vector administration completes the inventive concept.

The new claims introduce novel elements, including controlled release formulations, site-specific integration, and prenatal administration, which are not obvious from the original patent. These elements provide significant improvements in treatment efficacy, safety, and convenience, making the new inventive concept a substantial advancement over the existing art.

Alternative embodiments of the inventive concept could include different gene therapy vectors, promoters, or integration sites. Variations could also include the use of different biosensors or feedback loops to monitor treatment efficacy. These alternative embodiments and variations ensure broad conceptual coverage and potential for further development.

The enhanced gene therapy for MPS I treatment has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the areas of rare genetic disorders and gene therapy. The target market includes patients with MPS I, as well as healthcare providers and researchers seeking more effective and efficient treatment options.